August 08, 2025

Genetic Risk of Takayasu Arteritis Mapped

Large-scale genetic analyses identify multiple susceptibility loci for Takayasu arteritis, confirming HLA-B*52 as the strongest association and revealing immune pathways that vary by ancestry.

Conexiant

August 08, 2025

Unprompted Speech Changes Found in ME/CFS

Nearly 1 in 10 individuals with myalgic encephalomyelitis/chronic fatigue syndrome reported voice or speech changes in a recent survey, despite not being directly asked about these symptoms.

Conexiant

August 07, 2025

PsA Patients Accurately Report Nonjoint Symptoms

Patients with psoriatic arthritis consistently identify nonjoint symptoms such as dactylitis, psoriasis, and uveitis, demonstrating the clinical utility of patient-reported outcome measures.

Conexiant

August 07, 2025

Study Ties Asthma to Cardiometabolic Risk

Researchers studying nearly 29,000 middle-aged adults in Sweden found that individuals with asthma had significantly higher rates of hypertension, diabetes, and other conditions, along with elevated levels of systemic inflammation and blood sugar markers.

Conexiant

July 30, 2025

JAK Inhibitors May Improve Artery Health Markers

JAK inhibitor therapy targets inflammation and correlates with improvements in carotid artery measurements, while baseline vascular markers continue to predict cardiovascular risk.

Conexiant

August 04, 2025

Mood Shift Linked to Shoulder Pain Relief

Patients undergoing shoulder arthroplasty for rheumatoid arthritis show significant pain and function improvement, and data suggest emotional status may influence recovery dynamics over time.

Conexiant

July 31, 2025

FDA Approves Implantable Device for RA

“The approval of the SetPoint System, the first-in-class neuroimmune modulation platform, represents a transformative milestone in the management of autoimmune diseases."

Conexiant

July 25, 2025

Tofacitinib Curbs Inflammation, Not Thrombosis Risk

Tofacitinib dampens inflammatory cytokine production in rheumatoid arthritis models but fails to counteract endothelial prothrombotic responses, highlighting ongoing cardiovascular safety concerns.

Conexiant

July 15, 2025

Methotrexate Shows No Knee OA Symptom Benefit, Study Finds

A 52-week randomized clinical trial found no significant difference between methotrexate and placebo in reducing pain or effusion-synovitis in patients with inflammatory knee osteoarthritis.

Conexiant